Suvretta Capital Management Reduces Stake in Ultragenyx Pharmaceutical

Institutional investor cuts holdings in biopharmaceutical company by 11.4% in Q3

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Suvretta Capital Management LLC, an institutional investor, reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.4% in the third quarter, according to a filing with the Securities and Exchange Commission. Suvretta Capital Management now owns 2,019,000 shares of the biopharmaceutical company's stock, making it the 22nd largest holding in its portfolio.

Why it matters

Ultragenyx Pharmaceutical is a key player in the rare and ultra-rare genetic disorder treatment space, with several approved therapies in its commercial portfolio. Changes in institutional ownership can signal shifts in investor sentiment and impact the stock price.

The details

According to the filing, Suvretta Capital Management sold 259,000 shares of Ultragenyx Pharmaceutical during the third quarter. The institutional investor now owns approximately 2.09% of the biopharmaceutical company's outstanding shares, valued at $60.7 million at the end of the reporting period.

  • Suvretta Capital Management reduced its stake in Ultragenyx Pharmaceutical in the third quarter of 2026.

The players

Suvretta Capital Management LLC

An institutional investor and hedge fund that manages a portfolio of investments, including a position in Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Suvretta Capital Management's stake in Ultragenyx Pharmaceutical could signal a shift in investor sentiment towards the biopharmaceutical company, though the overall reasons behind the move are not entirely clear from the available information. Investors and analysts will likely continue to monitor Ultragenyx's performance and any further changes in institutional ownership.